Matthew Sanders

Matthew Sanders is vice-president, head of Global Drug Substance at GSK, Rixensart, Belgium.

Articles

Ipopba/Stock.adobe.com – Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

Introducing a New Concept for Value-Driven Acceleration in Biopharma Development

Matthew Sanders;Roland Mainil;Wael Chahim

October 2nd 2022

Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: December 9th 2024 | Updated: December 26th 2024

Recap Key Industry Trends for Viral Clearance and NGS

Published: December 7th 2024 | Updated: December 26th 2024

Enhancing Quality Through Training

Published: July 20th 2020 | Updated: December 26th 2024

Contact BioPharm International Editors

Published: July 19th 2020 | Updated: December 26th 2024

Editorial Information: BioPharm International Submission Guidelines and Editorial Calendars

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777